News & Updates
Filter by Specialty:
5-ASA use in paediatric CD common, deviates from recommended practices
Children with Crohn’s disease (CD) are often treated with 5-aminosalicylate (5-ASA) contrary to guidelines, and this practice is associated with a substantial delay in initiating biologic therapy, according to a study presented at this year’s Crohn's & Colitis Congress.
5-ASA use in paediatric CD common, deviates from recommended practices
07 Feb 2023Radiation therapy may raise colorectal cancer risk among Hodgkin's lymphoma survivors
Individuals who received radiation therapy for Hodgkin's lymphoma are at increased risk of colorectal cancer, as reported in a study.
Radiation therapy may raise colorectal cancer risk among Hodgkin's lymphoma survivors
06 Feb 2023Isolated anti-HBc positivity ups liver-related death risk
Isolated hepatitis B core antibody (anti-HBc) positivity appears to increase the risk of liver-related and liver cancer mortality, particularly when accompanied by a high fibrosis score, according to a study of Korean adults.
Isolated anti-HBc positivity ups liver-related death risk
06 Feb 2023SPOTLIGHT shines on zolbetuximab-chemo potential for gastric/GEJ cancer
A combination regimen comprising zolbetuximab and mFOLFOX6* chemotherapy (CT) regimen showed potential as first-line treatment for claudin-18.2-positive**/HER2-negative (CLDN18.2+/HER2–) locally advanced unresectable or metastatic gastric or gastroesophageal junction (G/GEJ) adenocarcinoma, according to the primary findings of the phase III SPOTLIGHT trial.
SPOTLIGHT shines on zolbetuximab-chemo potential for gastric/GEJ cancer
06 Feb 2023Prebiotic supplementation beneficial in mild to moderate ulcerative colitis
Oral supplementation with 1-kestose in patients with mild to moderate ulcerative colitis helps modulate the gut microbiome, which in turn contributes to clinical improvement, as reported in a study.
Prebiotic supplementation beneficial in mild to moderate ulcerative colitis
03 Feb 2023Add-on bevacizumab ups hypertension risk in CRC patients
The addition of bevacizumab (BVZ) to the standard regimen for the treatment of advanced colorectal cancer (CRC) appears to increase the risk of cardiovascular events, suggest the results of a meta-analysis presented at the recent ASCO Gastrointestinal Cancers Symposium (ASCO GI 2023).
Add-on bevacizumab ups hypertension risk in CRC patients
03 Feb 2023Palliative RT relieves pain in end-stage liver cancer
Treatment with single fraction radiation therapy (RT) results in lesser hepatic pain in most patients with end-stage hepatocellular carcinoma (HCC) or liver metastases, according to a study presented at the recent ASCO Gastrointestinal Cancers Symposium (ASCO GI 2023).